Aquinox Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Canaccord Genuity Raises Price Target on Aquinox Pharma (AQXP) to $22 on Supporting Evidence for AQX-1125
September 11, 2015 9:24 AM EDTCanaccord Genuity reiterated a Buy rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and raised the price target to $22.00 (from $10.00), on supporting evidence for AQX-1125, and ahead of FDA meetings. Aquinox will meet with FDA, on BPS/IC, for an end of P2 meeting in Nov. to finalize two Ph3's, the 1st of which should start by mid-2016.
Analyst... More
